- Home
- ESTC vs VTRS Comparison
ESTC vs VTRS Comparison
Compare ESTC & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTC
- VTRS
- Stock Information
- Founded
- ESTC 2012
- VTRS 1961
- Country
- ESTC Netherlands
- VTRS United States
- Employees
- ESTC N/A
- VTRS N/A
- Industry
- ESTC Computer Software: Prepackaged Software
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- ESTC Technology
- VTRS Health Care
- Exchange
- ESTC Nasdaq
- VTRS Nasdaq
- Market Cap
- ESTC N/A
- VTRS 9.0B
- IPO Year
- ESTC 2018
- VTRS N/A
- Fundamental
- Price
- ESTC $86.27
- VTRS $9.09
- Analyst Decision
- ESTC Buy
- VTRS Hold
- Analyst Count
- ESTC 26
- VTRS 4
- Target Price
- ESTC $128.42
- VTRS $10.50
- AVG Volume (30 Days)
- ESTC 1.7M
- VTRS 13.5M
- Earning Date
- ESTC 05-29-2025
- VTRS 05-08-2025
- Dividend Yield
- ESTC N/A
- VTRS 5.28%
- EPS Growth
- ESTC N/A
- VTRS N/A
- EPS
- ESTC N/A
- VTRS N/A
- Revenue
- ESTC $1,429,863,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- ESTC $18.75
- VTRS N/A
- Revenue Next Year
- ESTC $14.09
- VTRS $1.20
- P/E Ratio
- ESTC N/A
- VTRS N/A
- Revenue Growth
- ESTC 17.95
- VTRS N/A
- 52 Week Low
- ESTC $69.00
- VTRS $6.85
- 52 Week High
- ESTC $123.96
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- ESTC 53.00
- VTRS 65.82
- Support Level
- ESTC $81.03
- VTRS $8.47
- Resistance Level
- ESTC $88.50
- VTRS $8.76
- Average True Range (ATR)
- ESTC 3.01
- VTRS 0.27
- MACD
- ESTC 1.11
- VTRS 0.17
- Stochastic Oscillator
- ESTC 84.44
- VTRS 76.96
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.